Literature DB >> 2564553

Immunosuppressive properties of cyclosporin metabolites.

U Kunzendorf, J Brockmöller, F Jochimsen, I Roots, G Offerman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2564553     DOI： 10.1016/s0140-6736(89)92258-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

3.  Pharmacokinetic interaction between cyclosporin and diltiazem.

Authors:  J Brockmöller; H H Neumayer; K Wagner; W Weber; G Heinemeyer; H Kewitz; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate.

Authors:  M deLorgeril; P Boissonnat; C A Bizollon; J Guidollet; G Faucon; J P Guichard; R Levy-Prades-Sauron; S Renaud; G Dureau
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.